Trial in Progress: A Phase 1-2, First-in-human, Open Label, Dose Escalation and Expansion Study of AU-007, a Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients with Advanced Solid Tumors.